InflaRx N.V. (IFRX) Is Down 67% YTD. Here Is Why

InflaRx N.V. (NASDAQ:IFRX) is among the 13 Best German Stocks to Invest in Now, based on hedge fund sentiment. However, the stock has plunged by 67% year-to-date, with a significant slump over the past month, following the company’s announcement on May 28 to halt its Phase 3 trial for vilobelimab in pyoderma gangrenosum (PG) due to futility.

InflaRx N.V. (IFRX) Is Down 67% YTD. Here Is Why

A biochemist in a lab coat surrounded by medical vials and devices used in the development of a biopharmaceutical.

The clinical-stage biopharmaceutical company said that it decided on the recommendation of the Independent Data Monitoring Committee (IDMC), based on the data analysis of the first 30 patients in the study.

Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx N.V. (NASDAQ:IFRX) stated the following on the decision:

“We would like to thank the dedicated physicians and pyoderma gangrenosum patients for their participation in this pioneering study targeting a significant unmet need. While the outcome is not what we had hoped it would be, InflaRx remains committed to its goal of developing new therapies for underserved patients with chronic immune-dermatological conditions, including with our oral inhibitor of C5aR, INF904, with data expected this summer.”

InflaRx N.V. (NASDAQ:IFRX) has discontinued further development of vilobelimab in PG. Instead, it will prioritize its resources on the Phase 2a trial of INF904 to treat hidradenitis suppurativa and chronic spontaneous urticaria.

While we acknowledge the risk and potential of IFRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IFRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy and 13 Best Big Name Stocks to Buy Now.

Disclosure: None.